Compare Humana Inc (HUM) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Vale SA — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Vale SA for 109 Days on average.
| HUM | VALE | |
|---|---|---|
Market Cap | $46.49B | $57.32B |
Volume | 2,567,704 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $431.03 | $17.82 |
52-Week Low | $163.67 | $10.75 |
Typical Hold Time | 51 Days | 109 Days |
Enterprise Value | $53.84B | $73.56B |
Dividend Yield | 0.91% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
VALE stock trades at $13.42, down 1.4% on the day, reflecting recent pressure from earnings misses and sector-wide declines in steel producers. The technical outlook is bearish, with price near key support at $13, while fundamentals show declining net income margins and profit compression amid rising costs. Recent news highlights concerns over iron ore pricing and U.S. steel expansion plans impacting sentiment.
The investment case is mixed: analyst consensus leans Hold with a $16.21 price target, suggesting modest upside, but risks include cyclical commodity exposure, Brazilian regulatory issues, and margin pressure. Base metals growth offers a partial offset, but earnings consistency remains a challenge for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
